NO20081233L - Albumin fusjonsproteiner - Google Patents
Albumin fusjonsproteinerInfo
- Publication number
- NO20081233L NO20081233L NO20081233A NO20081233A NO20081233L NO 20081233 L NO20081233 L NO 20081233L NO 20081233 A NO20081233 A NO 20081233A NO 20081233 A NO20081233 A NO 20081233A NO 20081233 L NO20081233 L NO 20081233L
- Authority
- NO
- Norway
- Prior art keywords
- albumin infusion
- proteins
- nucleic acids
- vectors
- fusion proteins
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 238000001802 infusion Methods 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081233L true NO20081233L (no) | 2008-05-09 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081233A NO20081233L (no) | 2005-08-12 | 2008-03-10 | Albumin fusjonsproteiner |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (enExample) |
| JP (1) | JP2009504157A (enExample) |
| KR (1) | KR20080071119A (enExample) |
| AU (1) | AU2006280312A1 (enExample) |
| BR (1) | BRPI0614761A2 (enExample) |
| CA (1) | CA2618476A1 (enExample) |
| EC (1) | ECSP088262A (enExample) |
| IL (1) | IL189246A0 (enExample) |
| MA (1) | MA29836B1 (enExample) |
| MX (1) | MX2008001865A (enExample) |
| NO (1) | NO20081233L (enExample) |
| TN (1) | TNSN08064A1 (enExample) |
| WO (1) | WO2007021494A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| DK1729795T3 (en) | 2004-02-09 | 2016-04-11 | Human Genome Sciences Inc | Albumin fusion proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| BRPI0712383A2 (pt) | 2006-06-07 | 2012-07-10 | Human Genome Sciences Inc | proteìnas de fusão da albumina |
| CA2663352A1 (en) * | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2896630B1 (en) | 2007-01-30 | 2020-12-23 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| CA2749786A1 (en) | 2009-01-16 | 2010-07-22 | Jason Benjamin Bock | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
| WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| JP5813641B2 (ja) | 2009-08-24 | 2015-11-17 | アムニクス オペレーティング インコーポレイテッド | 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法 |
| EP3421491A3 (en) * | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Albumin variants |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| CA2800173C (en) * | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
| CN107261119A (zh) * | 2011-02-28 | 2017-10-20 | 独立行政法人国立循环器病研究中心 | 恶性肿瘤转移抑制用药物 |
| CN110272484A (zh) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| DK2717898T3 (en) | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| PL2804623T3 (pl) | 2012-01-12 | 2020-03-31 | Bioverativ Therapeutics Inc. | Chimeryczne polipeptydy czynnika viii i ich zastosowania |
| EP3564260B1 (en) | 2012-02-15 | 2022-10-19 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
| SI2822577T1 (sl) | 2012-02-15 | 2019-07-31 | Bioverativ Therapeutics Inc. | Rekombinantni proteini faktorja VIII |
| JP6441682B2 (ja) | 2012-03-16 | 2018-12-19 | アルブミディクス リミティド | アルブミン変種 |
| CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| HRP20200007T1 (hr) | 2012-07-11 | 2020-03-20 | Bioverativ Therapeutics Inc. | Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba |
| WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| CN105452290A (zh) | 2012-11-08 | 2016-03-30 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| PT3889173T (pt) | 2013-02-15 | 2023-10-10 | Bioverativ Therapeutics Inc | Gene do fator viii otimizado |
| EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
| SG10201913874TA (en) | 2013-03-15 | 2020-03-30 | Biogen Ma Inc | Factor ix polypeptide formulations |
| SG11201509313PA (en) | 2013-06-28 | 2016-01-28 | Biogen Ma Inc | Thrombin cleavable linker with xten and its uses thereof |
| WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
| US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| ES2927475T3 (es) | 2014-01-10 | 2022-11-07 | Bioverativ Therapeutics Inc | Proteínas quiméricas de factor VIII y usos de las mismas |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| JP6909203B2 (ja) | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法 |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| PT3411478T (pt) | 2016-02-01 | 2022-09-13 | Bioverativ Therapeutics Inc | Genes do fator viii otimizados |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| AU2017366709A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| JP2020517657A (ja) * | 2017-04-20 | 2020-06-18 | ノヴォ ノルディスク アー／エス | アルブミン融合タンパク質の精製方法 |
| WO2019032898A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | NUCLEIC ACID MOLECULES AND USES THEREOF |
| JP2021512126A (ja) | 2018-02-01 | 2021-05-13 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用 |
| TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療ａ型血友病的方法 |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| SG11202105880TA (en) | 2018-12-06 | 2021-07-29 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor ix |
| CA3152600A1 (en) | 2019-09-30 | 2021-04-08 | Andrew KROETSCH | Lentiviral vector formulations |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| JPWO2022030580A1 (enExample) * | 2020-08-06 | 2022-02-10 | ||
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| EP4603587A1 (en) * | 2022-10-11 | 2025-08-20 | JCR Pharmaceuticals Co., Ltd. | Fusion protein of serum albumin and physiologically-active protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277889B1 (en) * | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1729795T3 (en) * | 2004-02-09 | 2016-04-11 | Human Genome Sciences Inc | Albumin fusion proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en not_active Ceased
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080071119A (ko) | 2008-08-01 |
| TNSN08064A1 (en) | 2009-07-14 |
| ECSP088262A (es) | 2008-05-30 |
| WO2007021494A2 (en) | 2007-02-22 |
| EP1924596A2 (en) | 2008-05-28 |
| MX2008001865A (es) | 2008-04-15 |
| EP1924596A4 (en) | 2009-07-29 |
| JP2009504157A (ja) | 2009-02-05 |
| AU2006280312A1 (en) | 2007-02-22 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| MA29836B1 (fr) | 2008-10-03 |
| WO2007021494A3 (en) | 2007-07-26 |
| IL189246A0 (en) | 2008-08-07 |
| CA2618476A1 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081233L (no) | Albumin fusjonsproteiner | |
| NO20064059L (no) | Albumin fusjonsproteiner | |
| WO2008033413A3 (en) | Albumin fusion proteins | |
| WO2007146038A3 (en) | Albumin fusion proteins | |
| WO2005003296A3 (en) | Albumin fusion proteins | |
| WO2003060071A3 (en) | Albumin fusion proteins | |
| WO2003059934A3 (en) | Albumin fusion proteins | |
| WO2001079444A3 (en) | Albumin fusion proteins | |
| UA102503C2 (en) | Interleukin-13 binding proteins | |
| WO2003030821A3 (en) | Albumin fusion proteins | |
| WO2007092772A8 (en) | Protein formulations | |
| BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| WO2008142164A3 (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders | |
| ATE483027T1 (de) | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen | |
| DK1888641T3 (da) | Serumalbuminbindende proteiner | |
| BR112014018210A2 (pt) | moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| DK2369005T3 (da) | Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro | |
| WO2006042158A3 (en) | Methods and compositions for improving recombinant protein production | |
| WO2013003641A3 (en) | Serpin fusion polypeptides and methods of use thereof | |
| NO20052276L (no) | Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi | |
| WO2006052821A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases | |
| EP1896588A4 (en) | NOVEL Aβ BINDING PROTEIN, ITS PEPTIDE DERIVATIVES AND USES THEREOF | |
| WO2004087886A3 (en) | Modified adenoviral e1a constructs and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |